Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
Identifieur interne : 000489 ( Pmc/Corpus ); précédent : 000488; suivant : 000490Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
Auteurs : Tannaz Dehpouri ; Ghasem Rahmatpour Rokni ; Nematollah Ahangar Narenjbon ; Mohamad Goldust ; Paul S. Yamauchi ; Uwe Wollina ; Torello Lotti ; Leon Kircik ; Vito Giuseppe Di Lernia ; Sidharth Sonthalia ; Aleksandra Vojvodic ; Jacek Szepietowski ; Philippe Bahadoran ; Enzo Errichetti ; Carmen Cantisani ; Laura Atzori ; Elham Rezaee ; Zekayi Kutlubay ; Burhan Engin ; Steven Nistic ; Giovanni Damiani ; Rosalynn R. Z. Conic ; Andy Goren ; Leo Abrijan ; Georgi TchernevSource :
- Dermatology Reports [ 2036-7392 ] ; 2019.
Abstract
Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.
Url:
DOI: 10.4081/dr.2019.7965
PubMed: 31210916
PubMed Central: 6547029
Links to Exploration step
PMC:6547029Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study</title><author><name sortKey="Dehpouri, Tannaz" sort="Dehpouri, Tannaz" uniqKey="Dehpouri T" first="Tannaz" last="Dehpouri">Tannaz Dehpouri</name><affiliation><nlm:aff id="aff001">Student Research Committee,<institution>Mazandaran University of Medical Sciences</institution>, Ramsar International Branch,<addr-line>Ramsar, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rokni, Ghasem Rahmatpour" sort="Rokni, Ghasem Rahmatpour" uniqKey="Rokni G" first="Ghasem Rahmatpour" last="Rokni">Ghasem Rahmatpour Rokni</name><affiliation><nlm:aff id="aff002">Department of Dermatology,<institution>Mazandaran University of Medical Sciences</institution>, Sari,<addr-line>Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Narenjbon, Nematollah Ahangar" sort="Narenjbon, Nematollah Ahangar" uniqKey="Narenjbon N" first="Nematollah Ahangar" last="Narenjbon">Nematollah Ahangar Narenjbon</name><affiliation><nlm:aff id="aff003">Department of Pharmacology, Faculty of Pharmacy,<institution>Mazandaran University of Medical Sciences</institution>,<addr-line>Sari, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Goldust, Mohamad" sort="Goldust, Mohamad" uniqKey="Goldust M" first="Mohamad" last="Goldust">Mohamad Goldust</name><affiliation><nlm:aff id="aff002">Department of Dermatology,<institution>Mazandaran University of Medical Sciences</institution>, Sari,<addr-line>Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yamauchi, Paul S" sort="Yamauchi, Paul S" uniqKey="Yamauchi P" first="Paul S." last="Yamauchi">Paul S. Yamauchi</name><affiliation><nlm:aff id="aff004"><institution>Dermatology Institute and Skin Care Center</institution>, Santa Monica,<addr-line>California, USA</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff005">Division of Dermatology,<institution>David Geffen School of Medicine at University of California</institution>, Los Angeles,<addr-line>California, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wollina, Uwe" sort="Wollina, Uwe" uniqKey="Wollina U" first="Uwe" last="Wollina">Uwe Wollina</name><affiliation><nlm:aff id="aff006">Department of Dermatology and Allergology, Städtisches Klinikum Dresden,<institution>Academic Teaching Hospital of the Technical University of Dresden</institution>,<addr-line>Dresden, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name><affiliation><nlm:aff id="aff007">Department of Dermatology,<institution>“Guglielmo Marconi” University</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Kircik, Leon" sort="Kircik, Leon" uniqKey="Kircik L" first="Leon" last="Kircik">Leon Kircik</name><affiliation><nlm:aff id="aff008"><institution>Icahn School of Medicine at Mount Sinai</institution>,<addr-line>New York, NY, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lernia, Vito Giuseppe Di" sort="Lernia, Vito Giuseppe Di" uniqKey="Lernia V" first="Vito Giuseppe Di" last="Lernia">Vito Giuseppe Di Lernia</name><affiliation><nlm:aff id="aff009">Dermatology Unit,<institution>Santa Maria Nuova-IRCCS Hospital</institution>, Reggio Emilia,<addr-line>Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sonthalia, Sidharth" sort="Sonthalia, Sidharth" uniqKey="Sonthalia S" first="Sidharth" last="Sonthalia">Sidharth Sonthalia</name><affiliation><nlm:aff id="aff0010"><institution>Skinnocence: The Skin Clinic & Research Center</institution>, Gurugram, Haryana,<addr-line>India</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff0011"><institution>Dermasource India</institution>, Gurugram, Haryana,<addr-line>India</addr-line></nlm:aff></affiliation></author><author><name sortKey="Vojvodic, Aleksandra" sort="Vojvodic, Aleksandra" uniqKey="Vojvodic A" first="Aleksandra" last="Vojvodic">Aleksandra Vojvodic</name><affiliation><nlm:aff id="aff0012">Department of Dermatology and Venereology,<institution>Military Medical Academy</institution>,<addr-line>Belgrade, Serbia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Szepietowski, Jacek" sort="Szepietowski, Jacek" uniqKey="Szepietowski J" first="Jacek" last="Szepietowski">Jacek Szepietowski</name><affiliation><nlm:aff id="aff0013">Department of Dermatology, Venereology and Allergology,<institution>Wroclaw Medical University</institution>,<addr-line>Wroclaw, Poland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bahadoran, Philippe" sort="Bahadoran, Philippe" uniqKey="Bahadoran P" first="Philippe" last="Bahadoran">Philippe Bahadoran</name><affiliation><nlm:aff id="aff0014">Department of Dermatology,<institution>University Hospital of Nice</institution>,<addr-line>Nice, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Errichetti, Enzo" sort="Errichetti, Enzo" uniqKey="Errichetti E" first="Enzo" last="Errichetti">Enzo Errichetti</name><affiliation><nlm:aff id="aff0015">Department of Experimental and Clinical Medicine,<institution>Institute of Dermatology, University of Udine</institution>,<addr-line>Udine, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Cantisani, Carmen" sort="Cantisani, Carmen" uniqKey="Cantisani C" first="Carmen" last="Cantisani">Carmen Cantisani</name><affiliation><nlm:aff id="aff0016">Department of Dermatology, “Umberto I” Hospital,<institution>“Sapienza” University of Rome</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Atzori, Laura" sort="Atzori, Laura" uniqKey="Atzori L" first="Laura" last="Atzori">Laura Atzori</name><affiliation><nlm:aff id="aff0017">Dermatology Clinic, Department Medical Sciences and Public Health,<institution>University of Cagliari</institution>,<addr-line>Cagliari, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rezaee, Elham" sort="Rezaee, Elham" uniqKey="Rezaee E" first="Elham" last="Rezaee">Elham Rezaee</name><affiliation><nlm:aff id="aff0018">Department of Pharmaceutical Chemistry,<institution>School of Pharmacy, Shahid Beheshti University of Medical Sciences</institution>,<addr-line>Tehran, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Kutlubay, Zekayi" sort="Kutlubay, Zekayi" uniqKey="Kutlubay Z" first="Zekayi" last="Kutlubay">Zekayi Kutlubay</name><affiliation><nlm:aff id="aff0019">Department of Dermatology, Cerrahpasa Faculty of Medicine,<institution>University of Istanbul</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff></affiliation></author><author><name sortKey="Engin, Burhan" sort="Engin, Burhan" uniqKey="Engin B" first="Burhan" last="Engin">Burhan Engin</name><affiliation><nlm:aff id="aff0019">Department of Dermatology, Cerrahpasa Faculty of Medicine,<institution>University of Istanbul</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff></affiliation></author><author><name sortKey="Nistic, Steven" sort="Nistic, Steven" uniqKey="Nistic S" first="Steven" last="Nistic">Steven Nistic</name><affiliation><nlm:aff id="aff0020">Department of Health Sciences,<institution>“Magna Graecia” University of Catanzaro</institution>,<addr-line>Catanzaro, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Damiani, Giovanni" sort="Damiani, Giovanni" uniqKey="Damiani G" first="Giovanni" last="Damiani">Giovanni Damiani</name><affiliation><nlm:aff id="aff0021">Department of Medical and Surgical Pathophysiology and Transplantation,<institution>University of Milan</institution>, Dermatology Unit, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico,<addr-line>Milan, Italy</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff0022"><institution>Young Dermatologists Italian Network (YDIN), Centro Studi GISED</institution>,<addr-line>Bergamo, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Conic, Rosalynn R Z" sort="Conic, Rosalynn R Z" uniqKey="Conic R" first="Rosalynn R. Z." last="Conic">Rosalynn R. Z. Conic</name><affiliation><nlm:aff id="aff0023">Department of Dermatology,<institution>Case Western Reserve University</institution>, Cleveland,<addr-line>OH, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Goren, Andy" sort="Goren, Andy" uniqKey="Goren A" first="Andy" last="Goren">Andy Goren</name><affiliation><nlm:aff id="aff007">Department of Dermatology,<institution>“Guglielmo Marconi” University</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey=" Abrijan, Leo" sort=" Abrijan, Leo" uniqKey=" Abrijan L" first="Leo" last=" Abrijan">Leo Abrijan</name><affiliation><nlm:aff id="aff0024">Department of Dermatovenereology,<institution>Rijeka Clinical Hospital Center</institution>,<addr-line>Rijeka, Croatia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Tchernev, Georgi" sort="Tchernev, Georgi" uniqKey="Tchernev G" first="Georgi" last="Tchernev">Georgi Tchernev</name><affiliation><nlm:aff id="aff0025"><institution>Medical Institute of Ministry of Interior (MVR)</institution>, Department of Dermatology, Venereology and Dermatologic Surgery,<addr-line>Sofia, Bulgaria</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31210916</idno><idno type="pmc">6547029</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547029</idno><idno type="RBID">PMC:6547029</idno><idno type="doi">10.4081/dr.2019.7965</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000489</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000489</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study</title><author><name sortKey="Dehpouri, Tannaz" sort="Dehpouri, Tannaz" uniqKey="Dehpouri T" first="Tannaz" last="Dehpouri">Tannaz Dehpouri</name><affiliation><nlm:aff id="aff001">Student Research Committee,<institution>Mazandaran University of Medical Sciences</institution>, Ramsar International Branch,<addr-line>Ramsar, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rokni, Ghasem Rahmatpour" sort="Rokni, Ghasem Rahmatpour" uniqKey="Rokni G" first="Ghasem Rahmatpour" last="Rokni">Ghasem Rahmatpour Rokni</name><affiliation><nlm:aff id="aff002">Department of Dermatology,<institution>Mazandaran University of Medical Sciences</institution>, Sari,<addr-line>Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Narenjbon, Nematollah Ahangar" sort="Narenjbon, Nematollah Ahangar" uniqKey="Narenjbon N" first="Nematollah Ahangar" last="Narenjbon">Nematollah Ahangar Narenjbon</name><affiliation><nlm:aff id="aff003">Department of Pharmacology, Faculty of Pharmacy,<institution>Mazandaran University of Medical Sciences</institution>,<addr-line>Sari, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Goldust, Mohamad" sort="Goldust, Mohamad" uniqKey="Goldust M" first="Mohamad" last="Goldust">Mohamad Goldust</name><affiliation><nlm:aff id="aff002">Department of Dermatology,<institution>Mazandaran University of Medical Sciences</institution>, Sari,<addr-line>Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yamauchi, Paul S" sort="Yamauchi, Paul S" uniqKey="Yamauchi P" first="Paul S." last="Yamauchi">Paul S. Yamauchi</name><affiliation><nlm:aff id="aff004"><institution>Dermatology Institute and Skin Care Center</institution>, Santa Monica,<addr-line>California, USA</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff005">Division of Dermatology,<institution>David Geffen School of Medicine at University of California</institution>, Los Angeles,<addr-line>California, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Wollina, Uwe" sort="Wollina, Uwe" uniqKey="Wollina U" first="Uwe" last="Wollina">Uwe Wollina</name><affiliation><nlm:aff id="aff006">Department of Dermatology and Allergology, Städtisches Klinikum Dresden,<institution>Academic Teaching Hospital of the Technical University of Dresden</institution>,<addr-line>Dresden, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name><affiliation><nlm:aff id="aff007">Department of Dermatology,<institution>“Guglielmo Marconi” University</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Kircik, Leon" sort="Kircik, Leon" uniqKey="Kircik L" first="Leon" last="Kircik">Leon Kircik</name><affiliation><nlm:aff id="aff008"><institution>Icahn School of Medicine at Mount Sinai</institution>,<addr-line>New York, NY, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lernia, Vito Giuseppe Di" sort="Lernia, Vito Giuseppe Di" uniqKey="Lernia V" first="Vito Giuseppe Di" last="Lernia">Vito Giuseppe Di Lernia</name><affiliation><nlm:aff id="aff009">Dermatology Unit,<institution>Santa Maria Nuova-IRCCS Hospital</institution>, Reggio Emilia,<addr-line>Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sonthalia, Sidharth" sort="Sonthalia, Sidharth" uniqKey="Sonthalia S" first="Sidharth" last="Sonthalia">Sidharth Sonthalia</name><affiliation><nlm:aff id="aff0010"><institution>Skinnocence: The Skin Clinic & Research Center</institution>, Gurugram, Haryana,<addr-line>India</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff0011"><institution>Dermasource India</institution>, Gurugram, Haryana,<addr-line>India</addr-line></nlm:aff></affiliation></author><author><name sortKey="Vojvodic, Aleksandra" sort="Vojvodic, Aleksandra" uniqKey="Vojvodic A" first="Aleksandra" last="Vojvodic">Aleksandra Vojvodic</name><affiliation><nlm:aff id="aff0012">Department of Dermatology and Venereology,<institution>Military Medical Academy</institution>,<addr-line>Belgrade, Serbia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Szepietowski, Jacek" sort="Szepietowski, Jacek" uniqKey="Szepietowski J" first="Jacek" last="Szepietowski">Jacek Szepietowski</name><affiliation><nlm:aff id="aff0013">Department of Dermatology, Venereology and Allergology,<institution>Wroclaw Medical University</institution>,<addr-line>Wroclaw, Poland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bahadoran, Philippe" sort="Bahadoran, Philippe" uniqKey="Bahadoran P" first="Philippe" last="Bahadoran">Philippe Bahadoran</name><affiliation><nlm:aff id="aff0014">Department of Dermatology,<institution>University Hospital of Nice</institution>,<addr-line>Nice, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Errichetti, Enzo" sort="Errichetti, Enzo" uniqKey="Errichetti E" first="Enzo" last="Errichetti">Enzo Errichetti</name><affiliation><nlm:aff id="aff0015">Department of Experimental and Clinical Medicine,<institution>Institute of Dermatology, University of Udine</institution>,<addr-line>Udine, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Cantisani, Carmen" sort="Cantisani, Carmen" uniqKey="Cantisani C" first="Carmen" last="Cantisani">Carmen Cantisani</name><affiliation><nlm:aff id="aff0016">Department of Dermatology, “Umberto I” Hospital,<institution>“Sapienza” University of Rome</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Atzori, Laura" sort="Atzori, Laura" uniqKey="Atzori L" first="Laura" last="Atzori">Laura Atzori</name><affiliation><nlm:aff id="aff0017">Dermatology Clinic, Department Medical Sciences and Public Health,<institution>University of Cagliari</institution>,<addr-line>Cagliari, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rezaee, Elham" sort="Rezaee, Elham" uniqKey="Rezaee E" first="Elham" last="Rezaee">Elham Rezaee</name><affiliation><nlm:aff id="aff0018">Department of Pharmaceutical Chemistry,<institution>School of Pharmacy, Shahid Beheshti University of Medical Sciences</institution>,<addr-line>Tehran, Iran</addr-line></nlm:aff></affiliation></author><author><name sortKey="Kutlubay, Zekayi" sort="Kutlubay, Zekayi" uniqKey="Kutlubay Z" first="Zekayi" last="Kutlubay">Zekayi Kutlubay</name><affiliation><nlm:aff id="aff0019">Department of Dermatology, Cerrahpasa Faculty of Medicine,<institution>University of Istanbul</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff></affiliation></author><author><name sortKey="Engin, Burhan" sort="Engin, Burhan" uniqKey="Engin B" first="Burhan" last="Engin">Burhan Engin</name><affiliation><nlm:aff id="aff0019">Department of Dermatology, Cerrahpasa Faculty of Medicine,<institution>University of Istanbul</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff></affiliation></author><author><name sortKey="Nistic, Steven" sort="Nistic, Steven" uniqKey="Nistic S" first="Steven" last="Nistic">Steven Nistic</name><affiliation><nlm:aff id="aff0020">Department of Health Sciences,<institution>“Magna Graecia” University of Catanzaro</institution>,<addr-line>Catanzaro, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Damiani, Giovanni" sort="Damiani, Giovanni" uniqKey="Damiani G" first="Giovanni" last="Damiani">Giovanni Damiani</name><affiliation><nlm:aff id="aff0021">Department of Medical and Surgical Pathophysiology and Transplantation,<institution>University of Milan</institution>, Dermatology Unit, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico,<addr-line>Milan, Italy</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff0022"><institution>Young Dermatologists Italian Network (YDIN), Centro Studi GISED</institution>,<addr-line>Bergamo, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey="Conic, Rosalynn R Z" sort="Conic, Rosalynn R Z" uniqKey="Conic R" first="Rosalynn R. Z." last="Conic">Rosalynn R. Z. Conic</name><affiliation><nlm:aff id="aff0023">Department of Dermatology,<institution>Case Western Reserve University</institution>, Cleveland,<addr-line>OH, USA</addr-line></nlm:aff></affiliation></author><author><name sortKey="Goren, Andy" sort="Goren, Andy" uniqKey="Goren A" first="Andy" last="Goren">Andy Goren</name><affiliation><nlm:aff id="aff007">Department of Dermatology,<institution>“Guglielmo Marconi” University</institution>,<addr-line>Rome, Italy</addr-line></nlm:aff></affiliation></author><author><name sortKey=" Abrijan, Leo" sort=" Abrijan, Leo" uniqKey=" Abrijan L" first="Leo" last=" Abrijan">Leo Abrijan</name><affiliation><nlm:aff id="aff0024">Department of Dermatovenereology,<institution>Rijeka Clinical Hospital Center</institution>,<addr-line>Rijeka, Croatia</addr-line></nlm:aff></affiliation></author><author><name sortKey="Tchernev, Georgi" sort="Tchernev, Georgi" uniqKey="Tchernev G" first="Georgi" last="Tchernev">Georgi Tchernev</name><affiliation><nlm:aff id="aff0025"><institution>Medical Institute of Ministry of Interior (MVR)</institution>, Department of Dermatology, Venereology and Dermatologic Surgery,<addr-line>Sofia, Bulgaria</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">Dermatology Reports</title><idno type="ISSN">2036-7392</idno><idno type="eISSN">2036-7406</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Puig, L" uniqKey="Puig L">L Puig</name></author><author><name sortKey="Strohal, R" uniqKey="Strohal R">R Strohal</name></author><author><name sortKey="Husni, Me" uniqKey="Husni M">ME Husni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reich, K" uniqKey="Reich K">K Reich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sommer, Dm" uniqKey="Sommer D">DM Sommer</name></author><author><name sortKey="Jenisch, S" uniqKey="Jenisch S">S Jenisch</name></author><author><name sortKey="Suchan, M" uniqKey="Suchan M">M Suchan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Channual, J" uniqKey="Channual J">J Channual</name></author><author><name sortKey="Wu, Jj" uniqKey="Wu J">JJ Wu</name></author><author><name sortKey="Dann, Fj" uniqKey="Dann F">FJ Dann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gladman, Dd" uniqKey="Gladman D">DD Gladman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahlehoff, O" uniqKey="Ahlehoff O">O Ahlehoff</name></author><author><name sortKey="Gislason, Gh" uniqKey="Gislason G">GH Gislason</name></author><author><name sortKey="Charlot, M" uniqKey="Charlot M">M Charlot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kwon, O" uniqKey="Kwon O">O Kwon</name></author><author><name sortKey="Kang, Sj" uniqKey="Kang S">SJ Kang</name></author><author><name sortKey="Kang, Sh" uniqKey="Kang S">SH Kang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boscarino, Ja" uniqKey="Boscarino J">JA Boscarino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jialal, I" uniqKey="Jialal I">I Jialal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ruan, H" uniqKey="Ruan H">H Ruan</name></author><author><name sortKey="Lodish, Hf" uniqKey="Lodish H">HF Lodish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chandalia, M" uniqKey="Chandalia M">M Chandalia</name></author><author><name sortKey="Cabo Chan, Av" uniqKey="Cabo Chan A">AV Cabo-Chan</name></author><author><name sortKey="Devaraj, S" uniqKey="Devaraj S">S Devaraj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grundy, Sm" uniqKey="Grundy S">SM Grundy</name></author><author><name sortKey="Cleeman, Ji" uniqKey="Cleeman J">JI Cleeman</name></author><author><name sortKey="Daniels, Sr" uniqKey="Daniels S">SR Daniels</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, Lw" uniqKey="Johnson L">LW Johnson</name></author><author><name sortKey="Weinstock, Rs" uniqKey="Weinstock R">RS Weinstock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pereira, Rmr" uniqKey="Pereira R">RMR Pereira</name></author><author><name sortKey="De Carvalho, Jf" uniqKey="De Carvalho J">JF de Carvalho</name></author><author><name sortKey="Bonfa, E" uniqKey="Bonfa E">E. Bonfá</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Love, Tj" uniqKey="Love T">TJ Love</name></author><author><name sortKey="Qureshi, Aa" uniqKey="Qureshi A">AA Qureshi</name></author><author><name sortKey="Karlson, Ew" uniqKey="Karlson E">EW Karlson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Armstrong, Aw" uniqKey="Armstrong A">AW Armstrong</name></author><author><name sortKey="Harskamp, Ct" uniqKey="Harskamp C">CT Harskamp</name></author><author><name sortKey="Armstrong, Ej" uniqKey="Armstrong E">EJ Armstrong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahlehoff, O" uniqKey="Ahlehoff O">O Ahlehoff</name></author><author><name sortKey="Skov, L" uniqKey="Skov L">L Skov</name></author><author><name sortKey="Gislason, G" uniqKey="Gislason G">G Gislason</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prodanowich, S" uniqKey="Prodanowich S">S Prodanowich</name></author><author><name sortKey="Ma, F" uniqKey="Ma F">F Ma</name></author><author><name sortKey="Taylor, Jr" uniqKey="Taylor J">JR Taylor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nicola, Pj" uniqKey="Nicola P">PJ Nicola</name></author><author><name sortKey="Maradit Kremers, H" uniqKey="Maradit Kremers H">H Maradit-Kremers</name></author><author><name sortKey="Roger, Vl" uniqKey="Roger V">VL Roger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borja, F" uniqKey="Borja F">F Borja</name></author><author><name sortKey="Jury, Ec" uniqKey="Jury E">EC Jury</name></author><author><name sortKey="Mauri, C" uniqKey="Mauri C">C Mauri</name></author><author><name sortKey="Ehrenstein, Mr" uniqKey="Ehrenstein M">MR Ehrenstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Hk" uniqKey="Choi H">HK Choi</name></author><author><name sortKey="Hernan, Ma" uniqKey="Hernan M">MA Hernán</name></author><author><name sortKey="Seegar, Jd" uniqKey="Seegar J">JD Seegar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dessein, Ph" uniqKey="Dessein P">PH Dessein</name></author><author><name sortKey="Joffe, Bi" uniqKey="Joffe B">BI Joffe</name></author><author><name sortKey="Stanwix, Ae" uniqKey="Stanwix A">AE Stanwix</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garrett, S" uniqKey="Garrett S">S Garrett</name></author><author><name sortKey="Jenkinson, T" uniqKey="Jenkinson T">T Jenkinson</name></author><author><name sortKey="Kennedy, Lg" uniqKey="Kennedy L">LG Kennedy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prevoo, M" uniqKey="Prevoo M">M Prevoo</name></author><author><name sortKey="Van Hof, M" uniqKey="Van Hof M">M Van’t Hof</name></author><author><name sortKey="Kuper, H" uniqKey="Kuper H">H Kuper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marra, Ca" uniqKey="Marra C">CA Marra</name></author><author><name sortKey="Woolcott, Jc" uniqKey="Woolcott J">JC Woolcott</name></author><author><name sortKey="Kopec, Ja" uniqKey="Kopec J">JA Kopec</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Targher, G" uniqKey="Targher G">G Targher</name></author><author><name sortKey="Bertolini, L" uniqKey="Bertolini L">L Bertolini</name></author><author><name sortKey="Tessari, R" uniqKey="Tessari R">R Tessari</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Taylor, W" uniqKey="Taylor W">W Taylor</name></author><author><name sortKey="Gladman, D" uniqKey="Gladman D">D Gladman</name></author><author><name sortKey="Helliwell, P" uniqKey="Helliwell P">P Helliwell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cohen, Ad" uniqKey="Cohen A">AD Cohen</name></author><author><name sortKey="Gilutz, H" uniqKey="Gilutz H">H Gilutz</name></author><author><name sortKey="Henkin, Y" uniqKey="Henkin Y">Y Henkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johonsson, H" uniqKey="Johonsson H">H Johonsson</name></author><author><name sortKey="Mclnnes, Lb" uniqKey="Mclnnes L">Lb Mclnnes</name></author><author><name sortKey="Sattar, N" uniqKey="Sattar N">N Sattar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chin, Yy" uniqKey="Chin Y">YY Chin</name></author><author><name sortKey="Yu, Hs" uniqKey="Yu H">HS Yu</name></author><author><name sortKey="Li, Wc" uniqKey="Li W">WC Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khaw, K T" uniqKey="Khaw K">K-T Khaw</name></author><author><name sortKey="Wareham, N" uniqKey="Wareham N">N Wareham</name></author><author><name sortKey="Luben, R" uniqKey="Luben R">R Luben</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Rotte, Mc" uniqKey="De Rotte M">MC de Rotte</name></author><author><name sortKey="De Jong, Ph" uniqKey="De Jong P">PH de Jong</name></author><author><name sortKey="Den Boer, E" uniqKey="Den Boer E">E den Boer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perdan Pirkmajer, K" uniqKey="Perdan Pirkmajer K">K Perdan-Pirkmajer</name></author><author><name sortKey="Pirkmajer, S" uniqKey="Pirkmajer S">S Pirkmajer</name></author><author><name sortKey="Thevis, M" uniqKey="Thevis M">M Thevis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Jj" uniqKey="Wu J">JJ Wu</name></author><author><name sortKey="Rowan, Cg" uniqKey="Rowan C">CG Rowan</name></author><author><name sortKey="Bebchuk, Jd" uniqKey="Bebchuk J">JD Bebchuk</name></author><author><name sortKey="Anthony, Ms" uniqKey="Anthony M">MS Anthony</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Solomon, Dh" uniqKey="Solomon D">DH Solomon</name></author><author><name sortKey="Massarotti, E" uniqKey="Massarotti E">E Massarotti</name></author><author><name sortKey="Garg, R" uniqKey="Garg R">R Garg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gisondi, P" uniqKey="Gisondi P">P Gisondi</name></author><author><name sortKey="Cotena, C" uniqKey="Cotena C">C Cotena</name></author><author><name sortKey="Tessari, G" uniqKey="Tessari G">G Tessari</name></author><author><name sortKey="Girolomoni, G" uniqKey="Girolomoni G">G. Girolomoni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saraceno, R" uniqKey="Saraceno R">R Saraceno</name></author><author><name sortKey="Schipani, C" uniqKey="Schipani C">C Schipani</name></author><author><name sortKey="Mazzotta, A" uniqKey="Mazzotta A">A Mazzotta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cuchacovich, R" uniqKey="Cuchacovich R">R Cuchacovich</name></author><author><name sortKey="Espinoza, Lr" uniqKey="Espinoza L">LR Espinoza</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Reports</journal-id><journal-id journal-id-type="publisher-id">DR</journal-id><journal-title-group><journal-title>Dermatology Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7392</issn><issn pub-type="epub">2036-7406</issn><publisher><publisher-name>PAGEPress Publications, Pavia, Italy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31210916</article-id><article-id pub-id-type="pmc">6547029</article-id><article-id pub-id-type="doi">10.4081/dr.2019.7965</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dehpouri</surname><given-names>Tannaz</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rokni</surname><given-names>Ghasem Rahmatpour</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Narenjbon</surname><given-names>Nematollah Ahangar</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goldust</surname><given-names>Mohamad</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamauchi</surname><given-names>Paul S.</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wollina</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lotti</surname><given-names>Torello</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kircik</surname><given-names>Leon</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lernia</surname><given-names>Vito Giuseppe Di</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sonthalia</surname><given-names>Sidharth</given-names></name><xref ref-type="aff" rid="aff0010"><sup>10</sup></xref><xref ref-type="aff" rid="aff0011"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vojvodic</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="aff0012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Szepietowski</surname><given-names>Jacek</given-names></name><xref ref-type="aff" rid="aff0013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bahadoran</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff0014"><sup>14</sup></xref></contrib><contrib contrib-type="author"><name><surname>Errichetti</surname><given-names>Enzo</given-names></name><xref ref-type="aff" rid="aff0015"><sup>15</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cantisani</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="aff0016"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Atzori</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff0017"><sup>17</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rezaee</surname><given-names>Elham</given-names></name><xref ref-type="aff" rid="aff0018"><sup>18</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kutlubay</surname><given-names>Zekayi</given-names></name><xref ref-type="aff" rid="aff0019"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Engin</surname><given-names>Burhan</given-names></name><xref ref-type="aff" rid="aff0019"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nisticò</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff0020"><sup>20</sup></xref></contrib><contrib contrib-type="author"><name><surname>Damiani</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="aff0021"><sup>21</sup></xref><xref ref-type="aff" rid="aff0022"><sup>22</sup></xref></contrib><contrib contrib-type="author"><name><surname>Conic</surname><given-names>Rosalynn R.Z.</given-names></name><xref ref-type="aff" rid="aff0023"><sup>23</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goren</surname><given-names>Andy</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Čabrijan</surname><given-names>Leo</given-names></name><xref ref-type="aff" rid="aff0024"><sup>24</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tchernev</surname><given-names>Georgi</given-names></name><xref ref-type="aff" rid="aff0025"><sup>25</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>Student Research Committee,<institution>Mazandaran University of Medical Sciences</institution>, Ramsar International Branch,<addr-line>Ramsar, Iran</addr-line></aff><aff id="aff002"><label>2</label>Department of Dermatology,<institution>Mazandaran University of Medical Sciences</institution>, Sari,<addr-line>Iran</addr-line></aff><aff id="aff003"><label>3</label>Department of Pharmacology, Faculty of Pharmacy,<institution>Mazandaran University of Medical Sciences</institution>,<addr-line>Sari, Iran</addr-line></aff><aff id="aff004"><label>4</label><institution>Dermatology Institute and Skin Care Center</institution>, Santa Monica,<addr-line>California, USA</addr-line></aff><aff id="aff005"><label>5</label>Division of Dermatology,<institution>David Geffen School of Medicine at University of California</institution>, Los Angeles,<addr-line>California, USA</addr-line></aff><aff id="aff006"><label>6</label>Department of Dermatology and Allergology, Städtisches Klinikum Dresden,<institution>Academic Teaching Hospital of the Technical University of Dresden</institution>,<addr-line>Dresden, Germany</addr-line></aff><aff id="aff007"><label>7</label>Department of Dermatology,<institution>“Guglielmo Marconi” University</institution>,<addr-line>Rome, Italy</addr-line></aff><aff id="aff008"><label>8</label><institution>Icahn School of Medicine at Mount Sinai</institution>,<addr-line>New York, NY, USA</addr-line></aff><aff id="aff009"><label>9</label>Dermatology Unit,<institution>Santa Maria Nuova-IRCCS Hospital</institution>, Reggio Emilia,<addr-line>Italy</addr-line></aff><aff id="aff0010"><label>10</label><institution>Skinnocence: The Skin Clinic & Research Center</institution>, Gurugram, Haryana,<addr-line>India</addr-line></aff><aff id="aff0011"><label>11</label><institution>Dermasource India</institution>, Gurugram, Haryana,<addr-line>India</addr-line></aff><aff id="aff0012"><label>12</label>Department of Dermatology and Venereology,<institution>Military Medical Academy</institution>,<addr-line>Belgrade, Serbia</addr-line></aff><aff id="aff0013"><label>13</label>Department of Dermatology, Venereology and Allergology,<institution>Wroclaw Medical University</institution>,<addr-line>Wroclaw, Poland</addr-line></aff><aff id="aff0014"><label>14</label>Department of Dermatology,<institution>University Hospital of Nice</institution>,<addr-line>Nice, France</addr-line></aff><aff id="aff0015"><label>15</label>Department of Experimental and Clinical Medicine,<institution>Institute of Dermatology, University of Udine</institution>,<addr-line>Udine, Italy</addr-line></aff><aff id="aff0016"><label>16</label>Department of Dermatology, “Umberto I” Hospital,<institution>“Sapienza” University of Rome</institution>,<addr-line>Rome, Italy</addr-line></aff><aff id="aff0017"><label>17</label>Dermatology Clinic, Department Medical Sciences and Public Health,<institution>University of Cagliari</institution>,<addr-line>Cagliari, Italy</addr-line></aff><aff id="aff0018"><label>18</label>Department of Pharmaceutical Chemistry,<institution>School of Pharmacy, Shahid Beheshti University of Medical Sciences</institution>,<addr-line>Tehran, Iran</addr-line></aff><aff id="aff0019"><label>19</label>Department of Dermatology, Cerrahpasa Faculty of Medicine,<institution>University of Istanbul</institution>,<addr-line>Istanbul, Turkey</addr-line></aff><aff id="aff0020"><label>20</label>Department of Health Sciences,<institution>“Magna Graecia” University of Catanzaro</institution>,<addr-line>Catanzaro, Italy</addr-line></aff><aff id="aff0021"><label>21</label>Department of Medical and Surgical Pathophysiology and Transplantation,<institution>University of Milan</institution>, Dermatology Unit, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico,<addr-line>Milan, Italy</addr-line></aff><aff id="aff0022"><label>22</label><institution>Young Dermatologists Italian Network (YDIN), Centro Studi GISED</institution>,<addr-line>Bergamo, Italy</addr-line></aff><aff id="aff0023"><label>23</label>Department of Dermatology,<institution>Case Western Reserve University</institution>, Cleveland,<addr-line>OH, USA</addr-line></aff><aff id="aff0024"><label>24</label>Department of Dermatovenereology,<institution>Rijeka Clinical Hospital Center</institution>,<addr-line>Rijeka, Croatia</addr-line></aff><aff id="aff0025"><label>25</label><institution>Medical Institute of Ministry of Interior (MVR)</institution>, Department of Dermatology, Venereology and Dermatologic Surgery,<addr-line>Sofia, Bulgaria</addr-line></aff><author-notes><corresp id="cor1">Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran. <phone>+989125443956</phone> - <fax>+981133261248</fax>. <email>Dr.rokni@yahoo.com</email></corresp><fn fn-type="con"><p>Contributions: the manuscript has been read and approved by all the authors.</p></fn><fn fn-type="COI-statement"><p>Conflict of interest: the authors declare no potential conflict of interest.</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><day>23</day><month>1</month><year>2019</year></pub-date><volume>11</volume><issue>1</issue><elocation-id>7965</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>©Copyright T. Dehpouri et al., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Licensee PAGEPress, Italy</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</uri>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.</p></abstract><kwd-group><title>Key words</title><kwd>Psoriatic arthritis</kwd><kwd>Metabolic syndrome</kwd><kwd>HbA1c</kwd><kwd>Methotrexate</kwd></kwd-group><funding-group><funding-statement>Funding: none.</funding-statement></funding-group><counts><fig-count count="2"></fig-count><table-count count="1"></table-count><equation-count count="0"></equation-count><ref-count count="39"></ref-count><page-count count="5"></page-count></counts></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Psoriasis (PsO) is defined as a systemic, inflammatory dermatologic disease which affects approximately 2-3% of the global population.<sup><xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref></sup> Furthermore, psoriatic arthritis (PsA) can develop in 7-48% of all PsO subjects.<sup><xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref></sup> Patients with PsO and/or PsA are at a higher risk for development of other chronic pathologic diseases, which can complicate the management of these patients.<sup><xref rid="ref5" ref-type="bibr">5-7</xref></sup> Previous studies have proved that metabolic syndrome is related to a state of chronic low-grade inflammation.<sup><xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref9" ref-type="bibr">9</xref></sup> The underlying mechanism is partially unknown, but a group of cytokines, including tumor necrosis factor-α (TNF-α), have been evidenced to reduce the activity of insulin, contributing to insulin resistance.<sup><xref rid="ref9" ref-type="bibr">9-11</xref></sup> Unfortunately, there is limited data on association between metabolic syndrome and rheumatological disorders, even though a few studies have reported an increased incidence of metabolic syndrome in patients with rheumatologic disease.<sup><xref rid="ref12" ref-type="bibr">12-14</xref></sup> Besides, a few previous studies have indicated that there is an association between the metabolic syndrome and PsO.<sup><xref rid="ref15" ref-type="bibr">15</xref>,<xref rid="ref16" ref-type="bibr">16</xref></sup> Additionally, epidemiological evidence has proposed that systemic anti-inflammatory therapy might be helpful to decrease the risk of cardiovascular disease (CVD) in patients suffering from psoriasis.<sup><xref rid="ref17" ref-type="bibr">17</xref>,<xref rid="ref18" ref-type="bibr">18</xref></sup> Methotrexate (MTX) is an anti-rheumatic drug with its cytotoxic, anti-inflammatory and immune modulatory activities often used in psoriasis treatment. However, despite its use for the last 60 years, a close evaluation of its adverse effects and related risk factors has not been performed.<sup><xref rid="ref19" ref-type="bibr">19</xref></sup> In spite of growing concerns about cumulative toxicity, there are no detailed data for complications associated with an increased cumulative dose of MTX.<sup><xref rid="ref20" ref-type="bibr">20</xref></sup> Studies have demonstrated significant reductions in CVD-related mortality in patients treated with methotrexate.<sup><xref rid="ref21" ref-type="bibr">21</xref></sup> This finding has been attributed to the potent anti-inflammatory properties of methotrexate. <sup><xref rid="ref21" ref-type="bibr">21</xref>,<xref rid="ref22" ref-type="bibr">22</xref></sup> The aim of this study was to explore the effects of short-term methotrexate therapy on the blood levels of glucose and HbA1c in patients having psoriasis.</p></sec><sec id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title>Subjects</title><p>In this multicenter cross-sectional study, 27 patients (aged 30-60 years) with PsA from February 2016 to February 2018 were enrolled. The evaluation subjects included the evidence of lifestyle factors including smoking behavior, medical history, taking medications, presence of diabetes mellitus, hypertension, duration of disease, comorbidities, and clinical examinations which were obtained to discover the presence of PsA. Also, physical examination included recording the number of tender and swollen joints. To confirm the suspect of PsA we also performed joints radiogram and enthesis sonography. The diagnosis of PsA was established by standard criteria for psoriatic arthritis (CASPAR) with a score >3 points.<sup><xref rid="ref18" ref-type="bibr">18</xref></sup> Additionally, other parameters such as weight, height and waist circumference, body mass index (BMI) (kg/m<sup><xref rid="ref2" ref-type="bibr">2</xref></sup>) and blood pressure were also measured. The status of PsA was determined by the following standard indexes: the Bath Ankylosing Spondylitis Disease Activity Index,<sup><xref rid="ref23" ref-type="bibr">23</xref></sup> Disease Activity Score 28<sup>24</sup> and the health assessment questionnaire.<sup><xref rid="ref25" ref-type="bibr">25</xref></sup> Furthermore metabolic syndrome was determined via the International Diabetes Federation (IDF) 2004 and the National Cholesterol Education Program Adult Panel III (NCEP ATP III) (NCEP ATP III) 2001.<sup><xref rid="ref26" ref-type="bibr">26</xref>,<xref rid="ref27" ref-type="bibr">27</xref></sup> All patients were treated with oral methotrexate (7.5 mg/kg) weekly for three months. Before the collection of samples a written informed consent was obtained from each participant and ethical approval was granted by the ethics committee of the Mazandaran University of Medical Sciences, Pardis Unit, Ramsar, Iran.</p></sec><sec id="sec2-2"><title>Inclusion and exclusion criteria</title><p>In this study, PsA was diagnosed and confirmed by expert rheumatologists based on the CASPAR.<sup><xref rid="ref28" ref-type="bibr">28</xref></sup> Subjects with other inflammatory rheumatic diseases, myocardial infarction (MI), stroke, hyper-glycaemic status different from diabetes mellitus type 2 <italic>e.g</italic>. hyperthyroidism and hyperglicaemic, renal insufficiency, lung or liver or retroperitoneal fibrosis as well as patients who took anti-inflammatory drugs (NSAIDs or corticosteroids) were excluded from the study.</p></sec><sec id="sec2-3"><title>Blood analysis</title><p>Following serum sampling, they were kept at -80ºC until further processing. The HbA1c and erythrocyte sedimentation rate were primarily measured. Also, the serum concentrations of fasting blood sugar (FBS), total cholesterol, high-density lipoprotein cholesterol (HDL), triglycerides and C-reactive protein were measured using an automated analyzer (Model 912, Hitachi, Japan). All these parameters were examined before and after 12 weeks of treatment with methotrexate.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>Data was expressed as mean ± standard deviation (SD). Statistical analysis was conducted using SPSS version 18 (SPSS, Inc, Chicago, IL, USA). Differences were evaluated with the paired t test and chi-square test. The normality of data was checked using the one-sample Kolmogorov– Smirnov Test. The significant level of differences was set at 0.05.</p></sec></sec><sec id="sec1-3"><title>Results</title><p>Inclusion criteria were met by 35 patients. Among these, 27 patients continued the study with the mean age of 43.22±8.9. Nine (33.33%) patients were female and 18 (66.66%) were male. Demographic data and clinical features of patients before and after treatment are shown in <xref rid="table001" ref-type="table">Table 1</xref>. Hyperlipidemia was present in 7 (25.93%) patients at baseline for which 5 (18.52%) patients were using medications. Family history of stroke was present in 10 (37%) patients. In this study, 7 (25.93%) patients had a normal weight, 10 (37%) patients were overweight, and the other 10 patients were obese. HbA1c test was taken before and after using methotrexate. At baseline, 2 (7.41%) patients had diabetes while the rest were negative. There were no significant differences between HbA1c levels among genders before and after treatment with methotrexate (men: P=0.131, women: P=0.803) (<xref ref-type="fig" rid="fig001">Figure 1</xref>). According to the NCEP, 20 (74.04%) patients had the signs of metabolic syndrome while the other 7 (25.93%) did not. However, according to IDF, 19 (70.37%) patients showed the signs of metabolic syndrome and 8 (29.63%) patients didn’t. Furthermore, based on the NCEP index, HbA1c levels in PsA patients with metabolic syndrome were 5.7±0.9% before and 5.9±0.9% after methotrexate therapy (P=0.250). However, HbA1c levels in PsA patients without metabolic syndrome were 5.6±0.4 % and 5.7±0.5% before and after methotrexate therapy respectively (P=0.506) (<xref ref-type="fig" rid="fig002">Figure 2</xref>).</p></sec><sec id="sec1-4"><title>Discussion</title><p>Several studies have proposed that patients with PsA are at increased risk of CVD, obesity, diabetes and fatty liver disease. <sup><xref rid="ref29" ref-type="bibr">29-31</xref></sup>Additionally, previous reports have indicated that HbA1c as the primary screening tool for glucose intolerance and the major predictive factor for cardiovascular events.<sup><xref rid="ref32" ref-type="bibr">32</xref>,<xref rid="ref33" ref-type="bibr">33</xref></sup> In the present study, we prospectively examined the influence of short-term anti-psoriatic therapy with methotrexate on HbA1c.The findings showed that there was no significant alteration in the HbA1c levels after 12 weeks of continuous treatment. Previously, deRotte and Perdan-Pirkmajer <italic>et al.</italic> demonstrated that MTX reduced HbA1c concentrations in patients with RA or PsA.<sup><xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref></sup> However, in a retrospective cohort study, Wu <italic>et al.</italic> showed that PsO, PsA, and RA patients under treatment with TNF inhibitors associated with MTX displayed no significant differences in terms of the HbA1c level.<sup><xref rid="ref35" ref-type="bibr">35</xref></sup> Solomon <italic>et al.</italic> reported that there is a non-significantly lower risk of incident diabetes mellitus within patients suffering from PsA, PsO, or RA who were treated with methotrexate without tumor necrosis factor inhibitors or hydroxychloroquine. Nonetheless, in contrast to our study, Solomon <italic>et al.</italic> did not determine levels of HbA1C and FBS in their research.<sup><xref rid="ref36" ref-type="bibr">36</xref></sup> Furthermore, Gisondi <italic>et al.</italic> conducted a survey of two groups of psoriasis patients who were newly treated with methotrexate and demonstrated that there was no detected changes in the FBS level.<sup><xref rid="ref37" ref-type="bibr">37</xref></sup> In a 24-week retrospective study comparing TNF inhibitor, efalizumab, and methotrexate there was no significant alterations in FBS in any of the groups.<sup><xref rid="ref38" ref-type="bibr">38</xref></sup> Cuchacovich <italic>et al.</italic> examined 37 patients with RA treated with methotrexate (mean 34.7 months), and found no significant changes have been in FBS.<sup><xref rid="ref39" ref-type="bibr">39</xref></sup> All these reports are consistent with the results of our study. It appears that the administration of methotrexate for treatment of PsA does not have hyperglycaemic effects and thus it can be used in PsA patients with metabolic syndrome and diabetes. Moreover, the most important part of controlling the chronic disorders is following a healthy lifestyle along with proper medication. In addition, regular screening of diabetes by monitoring BMI, FBS levels, blood pressure and cholesterol levels may help early detection and management of new-onset diabetes in PsA patients being treated with methotrexate.</p></sec><sec id="sec1-5"><title>Conclusions</title><p>To conclude, the use of methotrexate was not related to a significant alteration in HbA1C or FBS levels in patients with PsA. According to the data obtained in this study, methotrexate can be used in the treatment of PsA patients without the risk of developing diabetes.</p></sec></body><back><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>L</given-names></name><name><surname>Strohal</surname><given-names>R</given-names></name><name><surname>Husni</surname><given-names>ME</given-names></name><etal></etal></person-group><article-title>Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-tosevere psoriasis and psoriatic arthritis</article-title>. <source>J Dermatol Treat</source><year>2015</year>;<volume>26</volume>:<fpage>7</fpage>-<lpage>15</lpage>.</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>K</given-names></name></person-group><article-title>The concept of psoriasis as a systemic inflammation: implications for disease management</article-title>. <source>J Eur Acad Dermatol Venereol</source><year>2012</year>;<volume>26</volume>:<fpage>3</fpage>-<lpage>11</lpage>.<pub-id pub-id-type="pmid">22356630</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>DM</given-names></name><name><surname>Jenisch</surname><given-names>S</given-names></name><name><surname>Suchan</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis</article-title>. <source>Archiv Dermatol Res</source><year>2007</year>;<volume>298</volume>:<fpage>321</fpage>.</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channual</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Dann</surname><given-names>FJ</given-names></name></person-group><article-title>Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis</article-title>. <source>Dermatol Ther</source><year>2009</year>;<volume>22</volume>:<fpage>61</fpage>-<lpage>73</lpage>.<pub-id pub-id-type="pmid">19222518</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name></person-group><article-title>Psoriatic arthritis from Wright’s era until today</article-title>. <source>J Rheumatol Suppl</source><year>2009</year>;<volume>83</volume>:<fpage>4</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">19661526</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlehoff</surname><given-names>O</given-names></name><name><surname>Gislason</surname><given-names>GH</given-names></name><name><surname>Charlot</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study</article-title>. <source>J Intern Med</source><year>2011</year>;<volume>270</volume>:<fpage>147</fpage>-<lpage>57</lpage>.<pub-id pub-id-type="pmid">21114692</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>O</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><etal></etal></person-group><article-title>Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy</article-title>. <source>Circ Cardiovasc Imaging</source><year>2017</year>;<volume>10</volume>:<fpage>e005934</fpage>.<pub-id pub-id-type="pmid">28679524</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boscarino</surname><given-names>JA</given-names></name></person-group><article-title>PTSD is a risk factor for cardiovascular disease: Time for increased screening and clinical intervention</article-title>. <source>Prevent Med</source><year>2013</year>;<volume>166</volume>:<fpage>806</fpage>-<lpage>14</lpage>.</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>The role of the laboratory in the diagnosis of the metabolic syndrome</article-title>. <source>Am J Clin Pathol</source><year>2009</year>;<volume>132</volume>:<fpage>161</fpage>-<lpage>2</lpage>.<pub-id pub-id-type="pmid">19605808</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>H</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α</article-title>. <source>Cytokine Growth Factor Rev</source><year>2003</year>;<volume>14</volume>:<fpage>447</fpage>-<lpage>55</lpage>.<pub-id pub-id-type="pmid">12948526</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandalia</surname><given-names>M</given-names></name><name><surname>Cabo-Chan</surname><given-names>AV</given-names><prefix>Jr</prefix></name><name><surname>Devaraj</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Elevated plasma highsensitivity C-reactive protein concentrations in Asian Indians living in the United States</article-title>. <source>J Clin Endocrinol Metabol</source><year>2003</year>;<volume>88</volume>:<fpage>377</fpage>.</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><etal></etal></person-group><article-title>Diagnosis and management of the metabolic syndrome</article-title>. <source>Circulation</source><year>2005</year>;<volume>112</volume>:<fpage>2735</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="pmid">16157765</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LW</given-names></name><name><surname>Weinstock</surname><given-names>RS</given-names></name></person-group><article-title>The metabolic syndrome: concepts and controversy</article-title>. <source>Mayo Clinic Proceed</source><year>2006</year>;<volume>81</volume>:<fpage>1615</fpage>-<lpage>20</lpage>.</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>RMR</given-names></name><name><surname>de Carvalho</surname><given-names>JF</given-names></name><name><surname>Bonfá</surname><given-names>E.</given-names></name></person-group><article-title>Metabolic syndrome in rheumatological diseases</article-title>. <source>Autoimmun Revi</source><year>2009</year>;<volume>8</volume>:<fpage>415</fpage>-<lpage>9</lpage>.</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>TJ</given-names></name><name><surname>Qureshi</surname><given-names>AA</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><etal></etal></person-group><article-title>Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006</article-title>. <source>Archiv Dermatol</source><year>2011</year>;<volume>147</volume>:<fpage>419</fpage>-<lpage>24</lpage>.</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>AW</given-names></name><name><surname>Harskamp</surname><given-names>CT</given-names></name><name><surname>Armstrong</surname><given-names>EJ</given-names></name></person-group><article-title>Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies</article-title>. <source>J Am Acad Dermatol</source><year>2013</year>;<volume>68</volume>:<fpage>654</fpage>-<lpage>62</lpage>.<pub-id pub-id-type="pmid">23360868</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlehoff</surname><given-names>O</given-names></name><name><surname>Skov</surname><given-names>L</given-names></name><name><surname>Gislason</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study</article-title>. <source>J Intern Med</source><year>2013</year>;<volume>273</volume>:<fpage>197</fpage>-<lpage>204</lpage>.<pub-id pub-id-type="pmid">22963528</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prodanowich</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>JR</given-names></name><etal></etal></person-group><article-title>Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis</article-title>. <source>J Am Acad Dermatol</source><year>2005</year>;<volume>52</volume>:<fpage>262</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">15692471</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicola</surname><given-names>PJ</given-names></name><name><surname>Maradit-Kremers</surname><given-names>H</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><etal></etal></person-group><article-title>The risk of congestive heart failure in rheumatoid arthritis: a population- based study over 46 years</article-title>. <source>Arthritis Rheum</source><year>2005</year>;<volume>52</volume>:<fpage>412</fpage>-<lpage>2</lpage>.<pub-id pub-id-type="pmid">15692992</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borja</surname><given-names>F</given-names></name><name><surname>Jury</surname><given-names>EC</given-names></name><name><surname>Mauri</surname><given-names>C</given-names></name><name><surname>Ehrenstein</surname><given-names>MR</given-names></name></person-group><article-title>Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis</article-title>. <source>Proceed Nation Acad Sci</source><year>2008</year>;<volume>105</volume>:<fpage>19396</fpage>-<lpage>401</lpage>.</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Hernán</surname><given-names>MA</given-names></name><name><surname>Seegar</surname><given-names>JD</given-names></name><etal></etal></person-group><article-title>Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study</article-title>. <source>Lancet</source><year>2002</year>;<volume>359</volume>:<fpage>1173</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">11955534</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dessein</surname><given-names>PH</given-names></name><name><surname>Joffe</surname><given-names>BI</given-names></name><name><surname>Stanwix</surname><given-names>AE</given-names></name></person-group><article-title>Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis – a pilot study</article-title>. <source>Arthritis Res</source><year>2002</year>;<volume>4</volume>:<fpage>12</fpage>-<lpage>8</lpage>.</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>S</given-names></name><name><surname>Jenkinson</surname><given-names>T</given-names></name><name><surname>Kennedy</surname><given-names>LG</given-names></name><etal></etal></person-group><article-title>A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index</article-title>. <source>J Rheumatol</source><year>1994</year>;<volume>21</volume>: <fpage>2286</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="pmid">7699630</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prevoo</surname><given-names>M</given-names></name><name><surname>Van’t Hof</surname><given-names>M</given-names></name><name><surname>Kuper</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheumatol</source><year>1995</year>;<volume>38</volume>:<fpage>44</fpage>-<lpage>8</lpage>.</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>CA</given-names></name><name><surname>Woolcott</surname><given-names>JC</given-names></name><name><surname>Kopec</surname><given-names>JA</given-names></name><etal></etal></person-group><article-title>A Comparision of generic, indirect utility measures (the HUl2,HUl3, SF- 6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis</article-title>. <source>Soc Sci Med</source><year>2005</year>;<volume>60</volume>:<fpage>1571</fpage>-<lpage>82</lpage>.<pub-id pub-id-type="pmid">15652688</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Bertolini</surname><given-names>L</given-names></name><name><surname>Tessari</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study</article-title>. <source>Diabetic Med</source><year>2006</year>;<volume>23</volume>:<fpage>1270</fpage>-<lpage>1</lpage>.<pub-id pub-id-type="pmid">17054609</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><collab>Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults</collab>. <article-title>Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title>. <source>JAMA</source><year>2001</year>;<volume>285</volume>:<fpage>2486</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="pmid">11368702</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>W</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Helliwell</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Classification criteria for psoriatic arthritis: development of new criteria from a large international study</article-title>. <source>Arthritis Rheumat</source><year>2006</year>;<volume>54</volume>:<fpage>2665</fpage>-<lpage>73</lpage>.<pub-id pub-id-type="pmid">16871531</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AD</given-names></name><name><surname>Gilutz</surname><given-names>H</given-names></name><name><surname>Henkin</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Psoriasis and the metabolic syndrome</article-title>. <source>Acta Dermato-venereol</source><year>2007</year>;<volume>87</volume>:<fpage>506</fpage>-<lpage>9</lpage>.</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johonsson</surname><given-names>H</given-names></name><name><surname>Mclnnes</surname><given-names>Lb</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name></person-group><article-title>Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence</article-title>. <source>Ann Rheum Dis</source><year>2012</year>;<volume>71</volume>:<fpage>480</fpage>-<lpage>3</lpage>.<pub-id pub-id-type="pmid">22294632</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>YY</given-names></name><name><surname>Yu</surname><given-names>HS</given-names></name><name><surname>Li</surname><given-names>WC</given-names></name><etal></etal></person-group><article-title>Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study</article-title>. <source>J Eur Acad Dermatol Venereol</source><year>2013</year>;<volume>27</volume>:<fpage>1262</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">23004680</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>K-T</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Glycated haemoglobin, diabetes, and mortality in men in Norfolk Cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)</article-title>. <source>BMJ</source><year>2001</year>;<volume>322</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">11141143</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Rotte</surname><given-names>MC</given-names></name><name><surname>de Jong</surname><given-names>PH</given-names></name><name><surname>den Boer</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis</article-title>. <source>Arthritis Rheumatol</source><year>2014</year>;<volume>66</volume>:<fpage>2026</fpage>-<lpage>36</lpage>.<pub-id pub-id-type="pmid">24692301</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdan-Pirkmajer</surname><given-names>K</given-names></name><name><surname>Pirkmajer</surname><given-names>S</given-names></name><name><surname>Thevis</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis</article-title>. <source>Scand J Rheumatol</source><year>2016</year>;<volume>45</volume>:<fpage>347</fpage>-<lpage>55</lpage>.<pub-id pub-id-type="pmid">26726793</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Rowan</surname><given-names>CG</given-names></name><name><surname>Bebchuk</surname><given-names>JD</given-names></name><name><surname>Anthony</surname><given-names>MS</given-names></name></person-group><article-title>No Association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients</article-title>. <source>J Drugs Dermatol</source><year>2015</year>;<volume>14</volume>:<fpage>159</fpage>-<lpage>66</lpage>.<pub-id pub-id-type="pmid">25689811</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Massarotti</surname><given-names>E</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Association between diseasemodifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis</article-title>. <source>JAMA</source><year>2011</year>;<volume>305</volume>:<fpage>2525</fpage>-<lpage>31</lpage>.<pub-id pub-id-type="pmid">21693740</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisondi</surname><given-names>P</given-names></name><name><surname>Cotena</surname><given-names>C</given-names></name><name><surname>Tessari</surname><given-names>G</given-names></name><name><surname>Girolomoni</surname><given-names>G.</given-names></name></person-group><article-title>Anti–tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study</article-title>. <source>J Eur Acad Dermatol Venereol</source><year>2008</year>;<volume>22</volume>:<fpage>341</fpage>-<lpage>4</lpage>.<pub-id pub-id-type="pmid">18005022</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraceno</surname><given-names>R</given-names></name><name><surname>Schipani</surname><given-names>C</given-names></name><name><surname>Mazzotta</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Effect of anti-tumor necrosis factor- α therapies on body mass index in patients with psoriasis</article-title>. <source>Pharmacol Res</source><year>2008</year>;<volume>57</volume>:<fpage>290</fpage>-<lpage>5</lpage>.<pub-id pub-id-type="pmid">18400510</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuchacovich</surname><given-names>R</given-names></name><name><surname>Espinoza</surname><given-names>LR</given-names></name></person-group><article-title>Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?</article-title><source>Clin Rheumatol</source><year>2009</year>;<volume>28</volume>:<fpage>1217</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">19517156</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The level of HbA1c based on the gender of psoriatic arthritis patients. The results are presented as mean ± SEM. Statistically significant differences between control and patients (P<0.05).</p></caption><graphic xlink:href="dr-11-1-7965-g001"></graphic></fig><fig id="fig002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The level of HbA1c based on the National Cholesterol Education Program Adult Panel index in psoriatic arthritis patients patients with and without metabolic syndrome. Results are presented as mean ± SEM. Statistically significant differences between control and patients (P<0.05).</p></caption><graphic xlink:href="dr-11-1-7965-g002"></graphic></fig><table-wrap id="table001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographic and clinical features of the study patients.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variation</th><th align="center" valign="top" rowspan="1" colspan="1">Patients with PsA before treatment n=27</th><th align="center" valign="top" rowspan="1" colspan="1">Patients with PsA after treatment n=27</th><th align="center" valign="top" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">43.22±8.9</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"> </td><td align="center" valign="top" rowspan="1" colspan="1"> </td><td align="center" valign="top" rowspan="1" colspan="1"> </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Men N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (66.7)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Women N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (33.3)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of diabetes N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of stroke N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (35.0)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of Hyperlipidemia N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FBS (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">103.2±30.2</td><td align="center" valign="top" rowspan="1" colspan="1">101.3±22.8</td><td align="center" valign="top" rowspan="1" colspan="1">624</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">165.7±26.9</td><td align="center" valign="top" rowspan="1" colspan="1">166.5±33.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.881</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">39.6±7.7</td><td align="center" valign="top" rowspan="1" colspan="1">42.8±6.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">98.7±22.7</td><td align="center" valign="top" rowspan="1" colspan="1">104.6±22.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="center" valign="top" rowspan="1" colspan="1">100% negative</td><td align="center" valign="top" rowspan="1" colspan="1">100% negative</td><td align="center" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESR (mm/hour)</td><td align="center" valign="top" rowspan="1" colspan="1">24.2±17.9</td><td align="center" valign="top" rowspan="1" colspan="1">23.5±17.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.722</td></tr></tbody></table><table-wrap-foot><fn><p>PsA, psoriatic arthritis patients; FBS, fasting blood sugar; HDL, high-density lipoprotein cholesterol; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000489 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000489 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6547029
|texte= Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31210916" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |